Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US. Positive feedback from world-leading glaucoma surgeons involved in the trial. MINIject is the only commercially available MIGS device targeting the supraciliary space. Commercial rollout continues following European approval in 2021
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
